nChroma Bio stops its only clinical study early, lays off 50%
A couple of years ago, two Boston-area biotech CEOs decided to merge their startups, hoping to survive a down market for genetic medicine companies. Jeff Walsh, the CEO of that combined company, nChroma Bio,
comments(0)
5-min edit window · permanent after that